The efficacy and safety of elbasvir/grazoprevir treatment in HCV genotype 1 patients in Taiwan-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The efficacy and safety of elbasvir/grazoprevir treatment in HCV genotype 1 patients in Taiwan

Published:2019-10-22 Issue:2 Volume:92 Page:219-226
ISSN:0146-6615
Container-title:Journal of Medical Virology
language:en
Short-container-title:J Med Virol

Author:

Tsai Tzu‐Cheng¹²,Deng Shin‐Tarng¹,Hsu Chao‐Wei³⁴^ORCID

Affiliation:

1. Department of PharmacyChang Gung Memorial Hospital Taoyuan Taiwan

2. Hsin Sheng Junior College of Medical Care and Management Taoyuan Taiwan

3. Department of Gastroenterology and HepatologyChang Gung Memorial Hospital Taoyuan Taiwan

4. Chang Gung University College of Medicine Taoyuan Taiwan

Publisher

Wiley

Subject

Infectious Diseases,Virology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jmv.25605

Reference15 articles.

1. Safety and efficacy of elbasvir/grazoprevir for the treatment of chronic hepatitis C: current evidence

2. Elbasvir/grazoprevir in Asia‐Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infection

3. Treatment of chronic hepatitis C in Asia: When East meets West

4. Treatment of hepatitis C with new fixed dose combinations

5. Elbasvir/grazoprevir (Zepatier) for hepatitis C virus infection;Early J;Am Fam Physician,2017

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of direct‐acting antiviral therapy for hepatitis C virus in elderly patients (≥65 years old): A systematic review and meta‐analysis;Journal of Viral Hepatitis;2022-04-06

2. Hepatocellular Carcinoma and Antiviral Therapies in HCV Chronic Infection;Advances in Hepatology;2021-07-28

3. Factors associated with treatment failure of direct‐acting antivirals for chronic hepatitis C: A real‐world nationwide hepatitis C virus registry programme in Taiwan;Liver International;2021-03-12

4. Elbasvir and grazoprevir for the treatment of hepatitis C;Expert Review of Anti-infective Therapy;2021-01-17

5. Drug–Drug Interactions of Newly Approved Direct-Acting Antiviral Agents in Patients with Hepatitis C;International Journal of General Medicine;2021-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3